Exercise of RHYO Options underwritten for $4.5m to $6.0m
Filed with ASX · · 5 pages · English
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Trading Halt
- Half-Year Financial Report and Appendix 4D
- Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
- ColoSTAT commercial deployment - First physician enrolled
- Rhythm Biosciences Signs Manufacturing Agreement
Later from Rhythm Biosciences
- RHY Executes SE Asian Genetype Distribution Agreement
- NATA Accredits ColoSTAT Clinical Testing Service
- First ColoSTAT Clinical Test Sale
- Response to ASX Query Letter
- Quarterly Activities Report and Appendix 4C
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences